Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zentiva Snaps Up Alvogen’s CEE Operations

Alvogen To Focus On Asia And Alvotech’s Biosimilars

Executive Summary

Acquiring Alvogen’s operations in central and eastern Europe will strengthen private equity-backed Zentiva’s presence in both the generics and OTC markets.

You may also be interested in...



Alvogen And Zentiva Complete CEE Deal

Alvogen’s central and eastern European business, which started up in 2010, has now been sold to the Zentiva group. Zentiva plans to combine both companies’ branded generics and OTC businesses in the CEE region.

Alvogen And Yas Strike MENA Licensing Deal

Alvogen has struck a licensing deal with Yas Holding that gives the firm exclusive distribution rights to a portfolio of 28 generics in the Middle East and North Africa region from 2020.

Advent Gains High-Potential ART Business Through Bharat Buy

With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel